Latest News – PSNC Main site
Pharmaceutical Services Negotiating Committee
Service case study: Hep C Testing supporting local case finding
In September 2020, the Community Pharmacy Hepatitis C Antibody Testing Service was added to the NHS Community Pharmacy Contractual Framework. The service is focused on provision of point of care testing for Hepatitis C (Hep C) antibodies to people who inject drugs (PWIDs), i.e. individuals who inject illicit drugs, e.g. steroids or heroin, but who...
April 2021 Price Concessions 1st Update
The Department of Health and Social Care (DHSC) has today granted the following initial list of price concessions: Drug Pack Size Price Concession Chlorpromazine 50mg tablets 28 £16.50 Eplerenone 25mg tablets 28 £12.00 Etoricoxib 60mg tablets 28 £16.24 Lamotrigine 100mg tablets 56 £5.14 Lamotrigine 50mg tablets 56 £4.50 Olmesartan medoxomil 10mg tablets 28 £8.85 Pregabalin...
Category M price re-determination for Amantadine 100mg capsules
The Department of Health and Social Care (DHSC) has redetermined the Category M price for Amantadine 100mg capsules in the April 2021 Drug Tariff. The Part VIIIA Basic Price published in the April 2021 Drug Tariff for Amantadine 100mg capsules (56) is now £26.34 instead of £11.25. Following the usual quarterly Category M pricing cycle,...
COVID-19 vacs: Collaborative working between Crest Pharmacy Group and PureGym
A community pharmacy group in the West Midlands is running a COVID-19 vaccination site from a gym to support local vaccination efforts. Whilst only small numbers of community pharmacy-led vaccination sites have been able to open so far, of them we are hearing incredible stories about how local stakeholders have collaborated to support the COVID-19...
April video update from PSNC’s CEO
The PSNC CEO video update for April is now available to watch. In the video PSNC Chief Executive Simon Dukes looks at the launch of the COVID-19 test distribution service. He praises the way community pharmacy teams have stepped up to provide this vital service, highlighting how – yet again – pharmacies have embraced the...
Early sign-up fee for C-19 test distribution service deadline approaches
Community pharmacy contractors who have not yet signed up to the new Advanced service – the NHS community pharmacy COVID-19 lateral flow device distribution service – but are intending to do so, are reminded that there is an early sign-up fee for those who sign up to provide the service by Sunday 18th April 2021....
C-19 test distribution service: recording and submitting transaction data
Pharmacies participating in the NHS community pharmacy COVID-19 lateral flow device distribution service must ask the person collecting the test kits the following three questions. The answers to questions 2 and 3 must be entered into the NHSBSA’s Manage Your Service (MYS) portal by the close of business on the pharmacy’s last trading day of the week. Have you collected...
C-19 test distribution service: submission of data on stock received
Pharmacies participating in the NHS community pharmacy COVID-19 lateral flow device distribution service (or ‘Pharmacy Collect’ as it is described in communications to the public) must make a record of the following information when they receive cartons of test kits from their wholesaler: Lot Number; Quantity of cartons; Supplying wholesaler; and Date of receipt. Download...
Ask PSNC: FAQs on the C-19 test distribution service
The Services Team at PSNC has received a number of queries on the NHS community pharmacy COVID-19 lateral flow device distribution service. Below are some of the questions asked this week. Q. Can I make supplies to a person under the age of 18 years? Where the person requesting supplies is under 18, the pharmacist...
Action: submitting last week’s data for the C-19 test distribution service on MYS
Community pharmacy contractors who have signed up to the COVID-19 lateral flow device distribution service, are asked to submit their data for last week (week commencing 5th April 2021) on the NHSBSA Manage Your Service (MYS) portal as soon as possible due to this function not being available last week. Due to a systems issue,...
PharmaTimes: PharmaTimes Website RSS
PharmaTimes - The latest news in healthcare and life sciences - PharmaTimes Website RSS
NICE unveils new strategy to improve patient access to innovative treatments
Five-year strategy will seek to transform key elements of organisation's approach to latest treatments
Phico Therapeutics gains £13.1m grant to advance antibacterial therapy
SASPject PT3.9 is designed for the treatment of hospital infections caused by Pseudomonas aeruginosa
TG Therapeutics’ ublituximab tops Sanofi’s Aubagio in MS trial
Ublituximab significantly reduced the annualised relapse rate in patients with relapsing forms of multiple sclerosis
New advice on COVID-19 vaccination for pregnant women in UK
JCVI advises pregnant women in the UK be offered COVID-19 vaccination at the same time as the rest of the population
EC approves new Sarclisa indication
Sarclisa has been approved in combination with a standard of care regimen for relapsed multiple myeloma
New subcutaneous formulation of Tysabri approved in UK
Multiple sclerosis treatment can now be administered subcutaneously or intravenously
EMA begins review of GSK/Vir’s COVID-19 antibody
The review will include an interim analysis of efficacy and safety data from the Phase III COMET-ICE trial
Roche’s SMA treatment Evrysdi demonstrates continued improvements in infants
Drug continuously improved motor function and survival in babies after 24 months of treatment
NICE recommends Alexion’s PNH treatment Ultomiris
C5 complement inhibitor approved to treat PNH in adult patients with haemolysis
Alchemab completes £60m Series A funding to advance novel antibody platform
The funding will be used to advance Alchemab’s novel platform to identify disease-modifying antibody therapeutics
Magic mushroom compound psilocybin shows ‘promise’ in depression
Researchers from Imperial College London say compound is at least as effective as a leading antidepressant in a therapeutic setting
Amylyx Pharma plans to file ALS therapy with the EMA this year
The previously-reported CENTAUR study of AMX0035 in 137 participants with ALS met its primary endpoint of slowing ALS progression
GSK decides to halt mid-stage feladilimab studies
British drugmaker has discontinued treatment with investigational drug in two cancer trials
Pfizer, Myovant begin dosing in relugolix contraceptive study
Dosing has begun in a Phase III study evaluating the contraceptive efficacy of relugolix combination tablet
Gilead’s Trodelvy scores accelerated approval in advanced bladder cancer
US Food and Drug Administration approved antibody drug conjugate based on Phase II trial results
Every sector of the pharmaceutical market is represented under one roof, this year in Madrid. Attending CPhI Worldwide is the most cost effective way to establish new business relationships, meet with global partners and stay updated on the latest industry trends.
Find out more: https://www.cphi.com/europe/